Drug Index


Mechanism :

Positive inotrope with direct pulmonary vasodilator (decrease both preload & afterload) activity, which increases cardiac output; these effects result from increases in cellular levels of cAMP as inamrinone inhibits myocardial cAMP phosphodiesterase.

Indication :

  • Congestive Heart Failure

Contraindications :

Hypersensitivity to inamrinone, milrinone and bisulfites.

Use with caution in Electrolyte abnormalities, Hypotension, Proarrhythmic effects, Insufficient cardiac filling pressure, Severe aortic or pulmonic valvular disease, Renal impairment, Concurrent use of disopyramide (may cause hypotension).

Dosing :

Load as in adults:
0.75 mg/kg IV over 3-5 minutes, then 3-5 mcg/kg/min IV maintenance infusion (in neonates) and 5-15 mcg/kg/min IV infusion (in children >28 days). Bolus dose may need to be repeated after 30 minutes. Total daily dose should not exceed 10 mg/kg/day. Therapeutic dosage range: 0.5-7 mcg/mL.

Adverse Effect :

Arrhythmia, thrombocytopenia, nausea, hypotension, fever, vomiting, abdominal pain, anorexia.

Interaction :

Anagrelide: Either increases effects of the other by pharmacodynamic synergism.
Milrinone: Either increases effects of the other by pharmacodynamic synergism.

Hepatic Dose :

Hepatotoxicity has occurred rarely. If acute transaminitis occurs along with clinical symptoms due idiosyncratic hypersensitivity reaction, inamrinone should be stopped. If transaminitis is not marked and the patient is asymptomatic, dose adjustment may be based on benefit/risk considerations.
12/14/2023 18:55:17 Inamrinone
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0